Abstract
Endemic Burkitt’s lymphoma (eBL) is the single most frequent and represents the vast majority of pediatric lymphomas in sub-Saharan Africa. Pathophysiology of eBL involves latent EBV infection and malaria. Thus far, chemotherapy-based approaches remain the mainstay of the treatment of BL. Despite the major challenges posed to the treatment of BL in high-endemicity and low-income countries, progress has been made, and treatment should be proposed. Current therapy of eBL yields cure rates in the range of 30–50 %, still largely inferior to the 70–90 % achievable in higher-income countries.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Molyneux EM, Rochford R, Griffin B et al (2012) Burkitt’s lymphoma. Lancet 379(9822):1234–1244
Zucca E, Rohatiner A, Magrath I, Cavalli F (2011) Epidemiology and management of lymphoma in low-income countries. Hematol Oncol 29(1):1–4
Lewis N, Young J, Hesseling PB, McCormick P, Wright N (2012) Epidemiology of Burkitt’s lymphoma in Northwest Province, Cameroon, 2003–2010. Paediatr Int Child Health 32(2):82–85
Taub R, Kirsch I, Morton C et al (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79(24):7837–7841
Pasqualucci L, Guglielmino R, Houldsworth J et al (2004) Expression of the AID protein in normal and neoplastic B cells. Blood 104(10):3318–3325
Preudhomme C, Dervite I, Wattel E et al (1995) Clinical significance of p53 mutations in newly diagnosed Burkitt’s lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol: Off J Am Soc Clin Oncol 13(4):812–820
Anderton E, Yee J, Smith P et al (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt’s lymphoma. Oncogene 27(4):421–433
Epstein MA, Achong BG (1964) Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1(7335):702–703
de-Thé G, Geser A, Day NE et al (1978) Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature 274(5673):756–761
de-The G (1977) Is Burkitt’s lymphoma related to perinatal infection by Epstein-Barr virus? Lancet 1(8007):335–338
Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4(10):757–768
Uchida J, Yasui T, Takaoka-Shichijo Y et al (1999) Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286(5438):300–303
Mancao C, Altmann M, Jungnickel B, Hammerschmidt W (2005) Rescue of “crippled” germinal center B cells from apoptosis by Epstein-Barr virus. Blood 106(13):4339–4344
Klein E, Kis LL, Klein G (2007) Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 26(9):1297–1305
Laichalk LL, Thorley-Lawson DA (2005) Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79(2):1296–1307
Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB (2006) Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A 103(40):14935–14940
Kalla M, Hammerschmidt W (2012) Human B cells on their route to latent infection – early but transient expression of lytic genes of Epstein-Barr virus. Eur J Cell Biol 91(1):65–69
Carpenter LM, Newton R, Casabonne D et al (2008) Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. Int J Cancer 122(6):1319–1323
Chene A, Donati D, Guerreiro-Cacais AO et al (2007) A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 3(6), e80
De Paoli P, Carbone A (2014) Pathogenesis of HIV-associated cancer. J Clin Oncol 32(27):3078
Patte C, Auperin A, Michon J et al (2001) The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97(11):3370–3379
Wakabi W (2008) Kenya and Uganda grapple with Burkitt lymphoma. Lancet Oncol 9(4):319
Webb S (2009) Customizing anticancer strategies to local needs. J Natl Cancer Inst 101(12):842–844
Hesseling PB, Molyneux E, Tchintseme F et al (2008) Treating Burkitt’s lymphoma in Malawi, Cameroon, and Ghana. Lancet Oncol 9(6):512–513
Bhakta N, Martiniuk ALC, Gupta S, Howard SC (2013) The cost effectiveness of treating paediatric cancer in low-income and middle-income countries: a case-study approach using acute lymphocytic leukaemia in Brazil and Burkitt lymphoma in Malawi. Arch Dis Child 98(2):155–160
Hesseling P, Molyneux E, Kamiza S, Israels T, Broadhead R (2009) Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Paediatr 29(1):29–34
Gopal S, Wood WA, Lee SJ et al (2012) Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood 119(22):5078–5087
Guggisberg K, Okorie C, Khalil M (2011) Cytopathology including fine-needle aspiration in sub-Saharan Africa: a Cameroon experience. Arch Pathol Lab Med 135(2):200–206
Hesseling P, Broadhead R, Mansvelt E et al (2005) The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer 44(3):245–250
Traoré F, Coze C, Atteby J-J et al (2011) Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer 56(1):70–76
Hesseling PB, Njume E, Kouya F et al (2012) The Cameroon 2008 Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy. Pediatr Hematol Oncol 29(2):119–129
Hesseling P, Israels T, Harif M et al (2013) Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting. Pediatr Blood Cancer 60(3):357–362
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Diop, S., Suarez, F. (2015). Burkitt’s Lymphoma: Physiopathology and Treatment of EBV-Associated Lymphomas. In: Droz, JP., Carme, B., Couppié, P., Nacher, M., Thiéblemont, C. (eds) Tropical Hemato-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18257-5_23
Download citation
DOI: https://doi.org/10.1007/978-3-319-18257-5_23
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18256-8
Online ISBN: 978-3-319-18257-5
eBook Packages: MedicineMedicine (R0)